AxoGen, Inc. (AXGN)

Market Cap	394.11M
Revenue (ttm)	133.96M
Net Income (ttm)	-28.82M
Shares Out	42.29M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,563
Open	9.92
Previous Close	9.90
Day's Range	9.03 - 10.02
52-Week Range	6.87 - 13.66
Beta	0.52
Analysts	Buy
Price Target	17.51 (+86.67%)
Earnings Date	Mar 14, 2023

About AXGN

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Ms. Karen Zaderej
• Employees: 428
• Stock Exchange: NASDAQ
• Ticker Symbol: AXGN

Financial Performance

In 2021, Axogen's revenue was $127.36 million, an increase of 13.41% compared to the previous year's $112.30 million. Losses were -$26.99 million, 13.4% more than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for AXGN stock is "Buy." The 12-month stock price forecast is $17.51, which is an increase of 86.67% from the latest price.

Price Target

$17.51

(86.67% upside)

Analyst Consensus: Buy